About Us
MAXONA Pharmaceuticals
is a clinical-stage pharmaceutical company leveraging innovation to develop the next generation of therapies to help patients MAXIMIZE LIFE.
MAXONA’s initial focus is on addressing the urgent need for new effective therapies that treat acute and chronic pain, without the side effects and addiction risks associated with NSAIDS and opioids.
Every day, more than 255 million Americans are living compromised lives, suffering from acute and chronic pain.
Our mission is to serve them.
MAX-001
MAXONA’s lead compound, MAX-001 is initially being developed in the U.S. to treat acute and chronic pain.
MAX-001 is an optimized formulation of an active molecule which is a non-NSAID, non-opioid, non-addictive pain killer with a more than 40-year clinical history of safe and effective use with patients in Europe and around the world. Numerous clinical studies published in peer-reviewed medical journals have demonstrated that it is as effective as opioids for treating pain, without the adverse side effects or addiction risk associated with opioids.
All IND-enabling pre-clinical studies and Phase I clinical trials have been completed for MAX-001 and having demonstrated a well-tolerated safety profile, the drug is expected to complete Phase II of clinical development in 2025.
Efficacy. Safety. Trust.
MAXONA Pharmaceuticals is committed to applying its intellectual property and unique expertise to develop patient-centric therapies that are efficacious, safe, trusted and clinically proven.
Expert
Leadership
MAXONA Pharmaceuticals is led by proven experts in neuroscience, drug development, drug formulation and delivery technology, clinical trial design and pharmacology.
